Flexibility                                             in Clinical Trials                                              se...
About the Evolution Summit 2012  The      Pharma        Network         –  marcus evans Summits group                     ...
Upcoming SlideShare
Loading in …5
×

Flexibility in Clinical Trials

386 views
323 views

Published on

Flexibility in Clinical Trials: Interview with: Prof Dr Geerd Weyer, Managing Director, ICRC-Weyer, a sponsor company at the marcus evans Evolution Summit 2012, on why drug development requires flexibility in the trial design.

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
386
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Flexibility in Clinical Trials

  1. 1. Flexibility in Clinical Trials service providers. They tend to believe has always been one of cooperation that the globalisation of drug and partnership with clients and other development gives them strength and service providers; bringing together allows them to avoid friction in our own strengths as a flexible processes that they would have if they specialist with the strengths of other had multiple interfaces and vendors. providers. They believe that this will help them save time and effort, but I consider Our philosophy is also reflected in the this to be a one-sided view. way we integrate services across departments. Likewise, our data Using the services of a niche or systems are optimised to seamlessly specialist provider could help them integrate data from various sources, accelerate clinical development. internal or external.Interview with: Prof Dr GeerdWeyer, Managing Director, ICRC- Would this limit innovation in anyWeyer way?Innovation in drug development When it comes to innovation, a service provider that can be flexible should be Processes must be adaptedrequires flexibility in the clinical trial preferred. Smaller organisations aredesign, not merely standardisation, able to bring in study-specificaccording to Prof Dr Geerd Weyer, solutions, while larger organisationsManaging Director, ICRC-Weyer.Every trial is unique and must be can bring in productivity and efficiency as they are able to streamline and to each studydesigned and treated as such, he adds. standardise services.From a contract research organisation There is a dichotomy betweenattending the upcoming marcus efficiency and productivity on the one What is key to clinical research andevans Evolution Summit 2012, Prof side, and innovation on the other. trial success?Dr Weyer talks about clinical trials and However, standardisation does nothow adaptability can accelerate always work. Processes must be The key is to have the right data inclinical development. adapted to each study. Clinical high quality when needed. This can be development is a process where achieved by recognising the value thatWhat would accelerate drug innovation and flexibility are needed, at a specialist provider in that respectivedevelopment and delivery/time to least as much as standardisation. area can bring, and by not totallymarket? relying on standard solutions. What is unique about yourIn the last few years, many large approach and philosophy? There is no single way for succeedingpharmaceutical companies have been in clinical development. Every trial iscontracting out clinical development We are well aware of the dichotomy I unique and must be designed andservices to single, globally acting mentioned before, but our philosophy treated as such.
  2. 2. About the Evolution Summit 2012 The Pharma Network – marcus evans Summits group Offering much more than any conference, seminar or trade show, this exclusive delivers peer-to-peer information meeting will bring together esteemed industry thought leaders and solution on strategic matters, professional providers to a highly focused and interactive networking event. trends and breakthrough innovations. www.evolution-summit.com Contact Please note that the Summit is a Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits closed business event and the Division number of participants strictly limited. Tel: + 357 22 849 313 Email: press@marcusevanscy.com For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.comAbout ICRC-WeyerLocated in Berlin, Germany, ICRC-Weyer is an all-Phase CRO with almost 20 years experience. The company provides its servicesfor the pharmaceutical and nutrition industries. These center on specialist solutions for independent medical review, expertconsulting and pharmacovigilance, which are integrated with the data management, statistical analysis and medical and regulatorywriting packages being offered.www.icrc-weyer.comAbout marcus evans Summitsmarcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discussstrategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity toindividually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.For more information, please visit: www.marcusevans.comUpcoming EventsDiscovery Summit (Europe) - www.discovery-summit.comDiscovery Summit (North America) - www.thediscoverysummit.comEvolution Asia Summit - www.evolutionasia-summit.comEvolution Summit (North America) - www.evolutionsummit.com.comTo view the web version of this interview, please click here: www.evolution-summit.com/GeerdWeyer

×